BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Conference call planned for later in Q4 2024 to provide updates on NurOwn® program
NEW YORK, Nov. 14, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2024 and provided a corporate update.
"BrainStorm's primary focus continues to be preparing for the upcoming Phase 3b registration trial of NurOwn in ALS," said Chaim Lebovits, President and CEO of Brainstorm. "We have carefully refined the trial design based on the learnings from our previous study, and we believe this will increase the probability of demonstrating a treatment effect. We are partnering with Pluri Inc., an established global leader in the development and manufacturing of cell-based therapeutics, to support the clinical supply needs. We have also selected a leading Clinical Research Organization and continue to work with investigators to establish multiple trial sites. We remain committed to the ALS community as we work to advance NurOwn and deliver a therapeutic option that we believe will make a difference for patients and their families."
Third Quarter 2024 and Recent Highlights
In October 2024, Brainstorm announced further details of the Phase 3b trial at the Annual Northeastern Amyotrophic Lateral Sclerosis Consortium (NEALS) Meeting .
In November 2024, BrainStorm entered into a Memorandum of Understanding (MOU) with Pluri Inc. (Pluri) to manufacture NurOwn® for use in the planned Phase 3b ALS trial. This MOU enables Brainstorm to begin the immediate transfer of its manufacturing technology and start producing NurOwn at Pluri's facility while the binding definitive agreement is being finalized.
Also at the NEALS meeting, Brainstorm presented a poster "Debamestrocel Long-Term Benefits on Survival and Neurodegeneration in ALS Expanded Access Program" featuring the results from 10 participants (6 NurOwn, 4 placebo) from the company's prior Phase 3 clinical trial (BCT-002-US) who enrolled in an open label Expanded Access Program (EAP). The EAP spanned two 28-week periods, with a break in time between the periods. Participants received a dose of NurOwn every 8 weeks, for a maximum of 6 doses over the 2 periods.
Participants in both treatment arms will be able to receive standard of care while on study.
The entry criteria are specifically targeting people living with ALS in the early stage of their disease. Key entry criteria will include: age 18 to 75 years old, ALS diagnosis defined by the revised El Escorial criteria as laboratory-supported probable, clinically probable, or definite, symptom onset within 24 months of screening, ≥2 points on each item of the ALSFRS-R, ALSFRS-R total score ≤45, and upright Slow Vital Capacity (SVC) ≥65% of predicted.
The primary efficacy endpoint will be a comparison of change in ALSFRS-R from baseline to week-24 (i.e. at the end of Part A) for NurOwn vs. placebo. Other outcome assessments will include CAFS (Clinical Assessment of Function & Survival), SVC, HHD (Hand-Held Dynamometry), survival, ALSAQ-40 questionnaire, the ZBI (Zarit Burden Interview), and disease biomarkers.
Up to approximately 200 participants with ALS are expected to enroll in the two-part Phase 3b trial, to receive 3 doses of either NurOwn (debamestrocel) or placebo for 24 weeks (Part-A), followed by an open label period during which all patients will receive 3 doses of NurOwn for another 24 weeks (Part B). Successful completion of Part A is expected to support a Biologic License Application (BLA).
Story Continues
Promising long term survival benefits were observed in NurOwn treated patients compared to matched controls in the PRO-ACT database. The survival curves revealed a statistically significant difference in favor of NurOwn (LRT, p= 0.0379) with a median survival time of 46.6 months for the treated group compared to 41.1 months for the matched control.
Consistent reductions in neurofilament light (NfL) were observed both during the randomized Phase 3 trial and in the subsequent EAP period, indicating that patients treated with NurOwn continued to see benefits from extended treatment. NfL is an important biomarker in ALS, measuring neurodegeneration and neural cell death. These data align with the understanding of NurOwn's mechanism of action.
Investor Conference Call and Webcast
BrainStorm is planning to host a conference call and webcast for the investment community later in Q4 2024 to provide further updates on the NurOwn Phase 3 program. Details will be provided in the near future.
Financial Results for the Third Quarter Ended September 30, 2024
Cash, cash equivalents, and restricted cash amounted to approximately $0.35 million, as of September 30, 2024.
Research and development expenses, net, in the third quarter ended September 30, 2024 were $1 million, compared to $3.3 million for the quarter ended September 30, 2023.
General and administrative expenses for the third quarter ended September 30, 2024 and 2023 were $2 million and $2.7 million, respectively.
Net loss for the third quarter ended September 30, 2024 was $2.7 million as compared to a net loss of $1.2 million for the quarter ended September 30, 2023.
Net loss per share for the third quarter ended September 30, 2024 and September 30, 2023 was $0.51 and $0.45, respectively.
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. BrainStorm holds the rights to clinical development and commercialization of the NurOwn® technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug designation status from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has completed a Phase 3 trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells and was supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989), and another grant from the ALS Association and I AM ALS. BrainStorm completed under an investigational new drug application a Phase 2 open-label multicenter trial (NCT03799718) of autologous MSC-NTF cells in progressive MS and was supported by a grant from the National MS Society (NMSS).
Notice Regarding Forward-Looking Statements
This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties, including statements regarding meetings with the probability of NurOwn demonstrating a treatment effect in ALS, the patient enrollment and dosing in the Phase 3b trial for NurOwn®, and the clinical development of NurOwn as a therapy for the treatment of ALS, the future availability of NurOwn to patients, and the future success of BrainStorm. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BrainStorm's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. These potential risks and uncertainties include, without limitation, management's ability to successfully achieve its goals, BrainStorm's ability to raise additional capital, BrainStorm's ability to continue as a going concern, prospects for future regulatory approval of NurOwn, whether BrainStorm's future interactions with the FDA will have productive outcomes, and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations, and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements.
CONTACTS
Media:
Lisa Guiterman
Phone: +1 202-330-3431
lisa.guiterman@gmail.com
IR:
Michael Wood
Phone: +1 646-597-6983
mwood@lifesciadvisors.com
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARIES
INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS
U.S. dollars in thousands
(Except share data)
September 30,
December 31,
2024
2023
Unaudited
Audited
U.S. $ in thousands
ASSETS
Current Assets:
Cash and cash equivalents
$
168
$
1,300
Other accounts receivable
40
51
Prepaid expenses and other current assets (Note 4)
156
548
Total current assets
$
364
$
1,899
Long-Term Assets:
Prepaid expenses and other long-term assets
$
22
$
22
Restricted Cash
181
185
Operating lease right of use asset (Note 5)
959
1,416
Property and Equipment, Net
499
686
Total Long-Term Assets
$
1,661
$
2,309
Total assets
$
2,025
$
4,208
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current Liabilities:
Accounts payables
$
4,603
$
4,954
Accrued expenses
865
1,240
Operating lease liability (Note 5)
570
603
Employees related liability
1,044
1,003
Total current liabilities
$
7,082
$
7,800
Long-Term Liabilities:
Operating lease liability (Note 5)
271
672
Warrants liability (Note 6)
729
594
Total long-term liabilities
$
1,000
$
1,266
Total liabilities
$
8,082
$
9,066
Stockholders' Deficit:
Stock capital: (Note 7)
14
13
Common Stock of $0.00005 par value - Authorized: 250,000,000 shares at September 30, 2024 and 100,000,000 shares at December 31, 2023 respectively; Issued and outstanding: 5,309,796 and 4,032,614 shares at September 30, 2024 and December 31, 2023 respectively (*)
Additional paid-in-capital
217,708
210,258
Treasury stocks
(116)
(116)
Accumulated deficit
(223,663)
(215,013)
Total stockholders' deficit
$
(6,057)
$
(4,858)
Total liabilities and stockholders' deficit
$
2,025
$
4,208
* Retroactively adjusted (See Note 7).
The accompanying notes are an integral part of the consolidated financial statements.
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARIES
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED)
U.S. dollars in thousands
(Except share data)
Nine months ended
Three months ended
September 30,
September 30,
2024
2023
2024
2023
Unaudited
Unaudited
Operating expenses:
Research and development, net
$
2,928
$
9,048
$
1,045
$
3,330
General and administrative
5,576
7,587
2,003
2,705
Operating loss
(8,504)
(16,635)
(3,048)
(6,035)
Financial (expense) income, net
(11)
91
(54)
(121)
Gain (loss) on change in fair value of Warrants liability (Note 6)
135
4,930
(394)
4,930
Net loss
$
(8,650)
$
(11,614)
$
(2,708)
$
(1,226)
Basic and diluted net loss per share from continuing operations
$
(1.80)
$
(4.35) (*)
$
(0.51)
$
(*) (0.45)
Weighted average number of shares outstanding used in computing basic and diluted net loss per share
4,793,026
2,683,700(*)
5,309,796
2,950,121(*)
* Retroactively adjusted (See Note 7).
The accompanying notes are an integral part of the consolidated financial statements.
Logo - https://mma.prnewswire.com/media/1166536/BrainStorm_Logo.jpg
Cision
View original content:https://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-announces-third-quarter-2024-financial-results-and-provides-corporate-update-302306076.html
SOURCE BrainStorm Cell Therapeutics Inc.
Hashtags
- BusinessHealthScienceFinance#ALS,NurOwn,NurOwn®,NEALS,EAP,ALSFRS-R,NASDAQ,AnnualNortheasternAmyotrophicLateralSclerosisConsortium,of,Debamestrocel,ALSExpandedAccessProgram,BCT-002-US,ExpandedAccessProgram,ElEscorial,ChaimLebovits,Other,Brainstorm,BrainStorm,Pluri,PRNewswire,BrainStormCellTherapeuticsInc,PluriInc.,PluriInc
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
America's biggest lender is closing its wallet — and investors and home buyers will feel it. Here's what to watch.
Over the past 40 years, Japan has helped bankroll Americans' lifestyle while its own economy sank into decades of stagnation. Now the tab's due, and it might cost the U.S. a fortune. The Japanese have been floating America's boat since the mid-1980s. Not out of kindness. Not out of stupidity. But because of a deal so sweet that nobody wanted to talk about it. 'He failed in his fiduciary duty': My brother liquidated our mother's 401(k) for her nursing home. He claimed the rest. I help my elderly mother every day and drive her to appointments. Can I recoup my costs from her estate? 'The situation is extreme': I'm 65 and leaving my estate to only one grandchild. Can the others contest my will? My new husband gave me a contract and told me to 'sign here' — but I refused. It was the best decision of my life. My daughter's boyfriend, a guest in my home, offered to powerwash part of my house — then demanded money Now the deal's going bad. Japan's drowning in debt, its politics are in chaos and it needs its money back. And when your biggest lender starts heading for the exits, it's time to pay attention. Japan holds $1.1 trillion in U.S. Treasury bonds. It's got more U.S. paper than any other country. But unlike China — the second-largest Treasury holders — Japan has never complained about it. Japan just kept buying, kept lending, kept quiet. But here's the thing about quiet money — when it stops being quiet, you've got problems. Look at Japan today: government debt at 235% of GDP — that's like owing your annual salary times 2.3 to Visa. Prime Minister Shigeru Ishiba hanging on to power like a cat on a screen door, with 21% approval after a series of fundraising scandals and economic missteps. You know what happens when your biggest lender is both broke and paralyzed? America's reliable ATM is about to display 'INSUFFICIENT FUNDS.' Picture this: 1945. World War II is over. America's got the guns, Japan's got the ruins. The U.S. cut a deal — military protection for economic cooperation. But the real magic trick came later. For the next 40 years, Japan rebuilt itself, accumulating dollars and using them for its own development. Japan went from making tin toys to Toyotas JP:7203 TM, from cheap radios to world-class electronics. By 1985, they'd completed their first miracle. Then came the second act. The Plaza Accord of 1985 — five finance ministers in a New York hotel room deciding to dismantle Japan's export machine. Japan signed on too, thinking they could manage it. They couldn't. The yen USDJPY shot up 50% against the U.S. dollar DXY in two years. Japan faced a choice: Watch its economic miracle turn into a pumpkin, or get creative. They got creative. Instead of converting their mountain of trade-surplus dollars to yen (which would have pushed the yen even higher), the Japanese did something beautiful. They started buying U.S. Treasury bonds. Mountains of them. It was perfect. The U.S. got to keep borrowing. Japan got to keep exporting. Nobody had to mention that the whole thing was a shell game. As economists have long warned, this recycling machine couldn't last forever. But that's a problem for the next guy. For the next 40 years — from 1985 to now — this recycling machine has been running nonstop. Japan made our Walkmans (Google it, kids), Americans would buy them with dollars, and then — here's the beautiful part — Japan would loan those dollars back to the U.S. by purchasing Treasury bonds. It's like paying your bartender with an IOU, then having him loan you money to keep drinking. Genius! Three major shifts are killing this arrangement, and they're all happening at once. First, demographics. Japan's aging population needs those savings for retirement, not for subsidizing American consumption. Turns out, elderly Japanese people prefer eating actual food to dining on Treasury bonds. Read: Why America's aging population will be a problem for stocks — and your retirement Second, debt. At 235% of GDP, Japan's government debt makes America's national debt look positively prudent, like comparing a shopaholic to someone who merely forgot to cancel their gym membership. As Japan's bond rates rise, the math becomes more impossible than explaining cryptocurrency to your grandmother. Third, politics. Prime Minister Ishiba's government hangs by a thread, with 21% approval after a series of fundraising scandals and economic missteps. You can't run a corner store with 21% approval, let alone a country. Adding to the pressure, there's declining demand for Japanese government bonds domestically. This forces Japan to raise interest rates, which in turn makes holding U.S. Treasurys even less attractive. When your own bonds can't find buyers, it's hard to justify buying someone else's. Enter Masayoshi Son, the SoftBank JP:9984 SFTBY billionaire who's become President Donald Trump's favorite Japanese dealmaker. He pledged $100 billion in U.S. investments in December, but that was just the warm-up act. Son doesn't look like a financial revolutionary. He looks more like your accountant's fun uncle. But this billionaire who makes Elon Musk look risk-averse has reportedly floated an idea more radical than Trump's Gaza resort plan: transform Japan's passive Treasury holdings into active investments in American companies through a joint sovereign wealth fund. According to financial press reports, this would mean converting government bonds into equity stakes in U.S. technology, infrastructure and energy projects. Picture this: Instead of Japan parking $1 trillion in government bonds yielding less than a savings account at the Bank of Mattress, this money would flow into U.S. technology, infrastructure and energy projects. Both nations would share the profits. Americans might even be able to buy shares, receiving dividends from Japanese investment in the U.S. economy. Of course, converting $1 trillion in bonds to equity investments would be fraught with risks — currency fluctuations, market volatility and political backlash on both sides of the Pacific. U.S. Treasury Secretary Scott Bessent would face a delicate task in making this transition without triggering a bond-market crisis — kind of like defusing a bomb while riding a unicycle. If Japan simply dumped its Treasury holdings, interest rates would spike faster than blood pressure at a tax audit. Time to panic? Not yet. But keep your running shoes handy. The immediate risks are clear: But the opportunity is equally significant. A U.S.-Japan investment fund could: This isn't just about financial engineering — though let's be honest, financial engineering is sexier than it sounds, like accounting's dangerous cousin who rides a motorcycle. It's about whether America can maintain access to foreign capital while reducing its debt dependence, kind of like keeping your rich friends while learning to pay for your own drinks. For 40 years, the U.S. has run its economy on other nations' savings like a teenager with Dad's credit card. That model is more exhausted than a parent of triplets. Critics will call this government interference in free markets. But free markets in international finance have always been about as real as professional wrestling — entertaining, but heavily choreographed. Every major economy practices industrial policy; America just outsourced its policy to allies and called it 'free trade.' Now the U.S. is bringing it home like a college kid with dirty laundry. Read: Why Trump's tax and spending bill isn't getting the bond market's vote Japan's quiet subsidy of American prosperity is ending. The U.S. Federal Reserve can't print its way out of this one — they've tried that trick more times than a birthday party magician. Congress can't tax its way out either, though God knows they'll probably try. The only path forward is a new bargain that transforms debt into equity, dependence into partnership. For American investors and homeowners, the message is crystal clear: The era of cheap money is over. Lock in fixed-rate mortgages while you can. Prepare for higher interest rates. And watch for announcements of new investment vehicles that could reshape global finance. The greatest risk isn't change — it's pretending the old system can continue. Japan's bondholders are already voting with their wallets. The only question is whether Washington can engineer an economic soft landing for the U.S. or whether the country is headed for the kind of turbulence that has flight attendants reaching for their own oxygen masks. Here's what to watch as these transitions unfold: For 40 years, Americans' have been drinking champagne on Japan's tab. Now it's closing time and they want to be paid in something besides IOUs. Welcome to the morning after. . More: Jamie Dimon's bond-market warnings put investors on alert to diversify outside U.S. Also read: The 'mother of all credit squeezes' is coming — hang on to your wallet 'I'm not wildly wealthy, but I've done well': I'm 79 and have $3 million in assets. Should I set up 529 plans for my grandkids? How do I make sure my son-in-law doesn't get his hands on my daughter's inheritance? Circle's stock is having another big day. What the blockbuster IPO has meant for other cryptocurrency plays. The S&P 500 closes at 6,000 as bulls aim for return to record territory 'I was pushed out of her life when she was 18': My estranged daughter, 29, misuses drugs. Should I leave her my Roth IRA? Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
34 minutes ago
- Forbes
Is Lululemon's Recent Pullback Your Perfect Entry Point?
CHINA - 2025/04/17: A shopper walks past the Canadian sportswear clothing band Lululemon store. ... More (Photo by Sebastian Ng/SOPA Images/LightRocket via Getty Images) Lululemon stock (NASDAQ:LULU) is currently trading at approximately $331 and seems undervalued based on its strong fundamentals, even though the stock often experiences volatility during turbulent market conditions. The company provided impressive Q1 2025 results, with revenue increasing by 7% to $2.37 billion and EPS rising to $2.60, just surpassing expectations. However, the market concentrated on a weaker-than-anticipated 1% increase in same-store sales and a revised full-year outlook, influenced in part by tariff-related pressures. The consequence? A swift 22% decline in after-hours trading that reflects more about short-term market sentiment than long-term intrinsic value. In spite of its high-performance profile, LULU behaves like a value stock. Lululemon trades at about 18x its trailing earnings (slightly lower than the historical average) and 19x price-to-free cash flow – both figures are beneath the S&P 500's averages—yet it is a company that consistently excels in revenue, margins, and return on capital. In comparison with its main competitor Nike, Lululemon is more affordable across significant profit metrics, with a reduced P/E and a more appealing P/FCF ratio. Investors are essentially acquiring Ferrari performance at Lexus pricing. Moreover, with a $32 billion market cap generating $1.6 billion in trailing free cash flow—a 5% cash flow yield, LULU appears to be more of a long-term wealth builder than a fluctuating apparel brand. For those looking for lower volatility compared to individual stocks, the Trefis High Quality portfolio offers an alternative – having outperformed the S&P 500 and yielding returns exceeding 91% since inception. Lululemon continues to showcase its growth capabilities. The company reports an impressive three-year revenue CAGR of 19%, which is more than three times the S&P 500's 5.5%. Over just the past year, it demonstrated 10% revenue growth, increasing annual sales to about $11 billion. Despite encountering macroeconomic challenges, the brand persists as a global growth powerhouse with an expanding international presence and remarkable efficiency. Its operating margin over the last four quarters of 23.7% nearly doubles the S&P 500's 13.2%, while its operating cash flow and net income margins (21.5% and 17.1%, respectively) significantly outperform broader market averages. These figures are not merely good—they're elite. Lululemon's balance sheet resembles a fortress. With a debt-to-equity ratio of just 4.9%, it is significantly below the S&P 500 average of 19.9%. Additionally, its cash-to-assets ratio of 26.1% far exceeds the market's 13.8%. This immaculate financial status provides Lululemon with both strength during downturns and the ability to invest in further growth. There's no way to sugarcoat it: Lululemon has experienced dramatic declines during market corrections. It dropped 46% during the downturn of 2022 (compared to the S&P's 25%), fell 47% in the early 2020 COVID-19 shock (versus 34%), and was extremely affected during the 2008 crash, plummeting 92% (compared to 57%). Investors must recognize that with LULU, strong fundamentals don't necessarily provide protection against sharp changes in sentiment. Our dashboard How Low Can Stocks Go During A Market Crash illustrates how major stocks performed during and after the last six market crashes. Lululemon checks nearly every box: strong growth, solid profitability, and a fortified balance sheet, with the only drawback being its susceptibility during market downturns. Trading at a slight discount relative to its strong performance profile, the recent Q1 results, which included mixed outcomes and cautious guidance, underscore immediate challenges while preserving the integrity of long-term fundamentals. Nonetheless, you could also consider the Trefis Reinforced Value (RV) Portfolio, which has surpassed its all-cap stocks benchmark (a combination of the S&P 500, S&P mid-cap, and Russell 2000 benchmark indices) to yield strong returns for investors. Why is that? The quarterly rebalanced mix of large-, mid- and small-cap RV Portfolio stocks offered a responsive strategy to capitalize on positive market conditions while limiting losses during downturns, as detailed in RV Portfolio performance metrics.
Associated Press
2 hours ago
- Associated Press
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Zenas To Contact Him Directly To Discuss Their Options If you purchased or otherwise acquired stock of Zenas pursuant and/or traceable to Zenas' registration statement for the initial public offering held on or about September 13, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - June 8, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Zenas BioPharma, Inc. ('Zenas' or the 'Company') (NASDAQ: ZBIO) and reminds investors of the June 16, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. [ This image cannot be displayed. Please visit the source: ] Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Zenas BioPharma materially overstated the amount of time it would be able to fund its operations using existing cash and expected net proceeds from the IPO; and (2) as a result, defendants' public statements were materially false and misleading at all relevant times and negligently prepared. When the true details entered the market, the lawsuit claims that investors suffered damages. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Zenas' conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Zenas BioPharma class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. To view the source version of this press release, please visit
